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High-dimensional detection of imaging response to treatment
in multiple sclerosis
Baris Kanber1,2,3, Parashkev Nachev3,4, Frederik Barkhof1,2,3,5, Alberto Calvi2, Jorge Cardoso1,3, Rosa Cortese2, Ferran Prados1,2,
Carole H. Sudre1, Carmen Tur 2, Sebastien Ourselin1,3 and Olga Ciccarelli2,3
Changes on brain imaging may precede clinical manifestations or disclose disease progression opaque to conventional clinical
measures. Where, as in multiple sclerosis, the pathological process has a complex anatomical distribution, such changes are not
easily detected by low-dimensional models in common use. This hinders our ability to detect treatment effects, both in the
management of individual patients and in interventional trials. Here we compared the ability of conventional models to detect an
imaging response to treatment against high-dimensional models incorporating a wide multiplicity of imaging factors. We used
fully-automated image analysis to extract 144 regional, longitudinal trajectories of pre- and post- treatment changes in brain
volume and disconnection in a cohort of 124 natalizumab-treated patients. Low- and high-dimensional models of the relationship
between treatment and the trajectories of change were built and evaluated with machine learning, quantifying performance with
receiver operating characteristic curves. Simulations of randomised controlled trials enrolling varying numbers of patients were
used to quantify the impact of dimensionality on statistical efﬁciency. Compared to existing methods, high-dimensional models
were superior in treatment response detection (area under the receiver operating characteristic curve= 0.890 [95% CI=
0.885–0.895] vs. 0.686 [95% CI= 0.679–0.693], P < 0.01]) and in statistical efﬁciency (achieved statistical power= 0.806 [95% CI=
0.698–0.872] vs. 0.508 [95% CI= 0.403–0.593] with number of patients enrolled= 50, at α= 0.01). High-dimensional models based
on routine, clinical imaging can substantially enhance the detection of the imaging response to treatment in multiple sclerosis,
potentially enabling more accurate individual prediction and greater statistical efﬁciency of randomised controlled trials.
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INTRODUCTION
The value of any therapy is ultimately determined by its impact on
patients’ lives. Both clinical and investigational measures are
merely surrogates of impact, the former favoured owing to its
perceived directness. Nonetheless, under two circumstances the
imaging response to an intervention may be more important than
the clinical. First, when imaging changes precede clinical
manifestations they can provide grounds for earlier intervention.
Oncologists, for example, rarely wait for an imaging relapse to
become clinically obvious. Second, when the impact on quality-of-
life is difﬁcult to quantify, an imaging response may obtain greater
real-world accuracy. In focal brain injury, for example, though the
behavioural effects of prefrontal damage obvious on imaging can
be devastating, even sophisticated neuropsychological testing
often fails to detect them.1
Both these circumstances apply to multiple sclerosis. Imaging
changes precede clinical deterioration, support the diagnosis and
predict the prognosis of multiple sclerosis,2 and are surrogates for
relapses.3 Clinical measures neither capture all affected functional
domains nor the progression of disability.4 Furthermore, a divide
exists between detecting an individual response in routine clinical
care, and detecting an “average” response within clinical trials.
A means of detecting an imaging response to treatment is
therefore needed: the question is how best to achieve it. The
conventional approach identiﬁes a small set of univariate
“biomarkers”, such as the number of lesions and volume, indexing
their response to therapy within univariate or low-dimensional,
multivariate statistical models. But brain pathology here extends
beyond visible lesions, involves grey and white matter, and
interacts with the complexity of the brain’s functional anatomy in
a way that only a large number of features could adequately
characterise.5 Indeed, multivariate patterns of grey matter atrophy
are both complex and clinically relevant.6 Low-dimensional
models that ignore this complexity are therefore bound to be
insensitive to treatment effects.
Until recently, the difﬁculty of extracting multiple imaging
features and evaluating them within high-dimensional multi-
variate models has limited the application of complex modelling
to this problem. But automated tissue segmentation and
anatomical parcellation can now quantify regional brain atrophy
at high spatial resolution,7 and white matter lesion segmentation,
coupled with tractography, can deﬁne complex patterns of grey
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matter disconnection, yielding a high-dimensional, multivariate
“ﬁngerprint” of the brain. Conventional, low-dimensional models
can now be compared with the proposed, high-dimensional
models, quantifying the impact on the sensitivity and speciﬁcity
for detecting a treatment response.8–12
Crucially, this approach is applicable to real-world, heteroge-
neous magnetic resonance imaging (MRI) data. Where the
biological signal is high-dimensional, conveyed in the interactions
between many features, it becomes resistant to noise and baseline
variability, given sufﬁcient data and the right modelling technique.
The ability to use real-world, heterogeneous MRI data would make
it possible for high-dimensional modelling to be readily intro-
duced into clinical practice and interventional clinical trials.
Recent publications have shown the value of high-dimensional
modelling based on brain lesion patterns in predicting conversion
to multiple sclerosis,9 future disease activity10 and treatment
responders,11 establishing the theoretical basis for the work
described in this paper. Given that brain morphology is also
important in the prediction of clinical outcomes,12 one can
hypothesise that the addition of the latter would beneﬁt the
detection of imaging response to treatment, and we test this
hypothesis.
Here we examined an unselected cohort of relapsing-remitting
patients with multiple sclerosis treated with natalizumab, and
imaged with standard-of-care MRI. Our aim was to compare the
performance of conventional low- and the proposed, high-
dimensional models in detecting the imaging response to the
treatment in the real-world clinical setting, and by simulating a
randomised, clinical trial. We further sought to deﬁne the potential
applications of such models.
RESULTS
Performance ﬁgures
The best high-dimensional model (ERT classiﬁer) yielded a
signiﬁcantly superior performance than the best, conventional,
low-dimensional model (ERT classiﬁer): high-dimensional ERT
model AUC= 0.890 (95% conﬁdence intervals (CIs): 0.885–0.895)
vs. low-dimensional ERT model AUC= 0.686 (95% CIs:
0.679–0.693) (P < 0.01) (Fig. 1a). This reﬂected an individual
accuracy of 86.5% (95% CIs: 85.9–87.0), a sensitivity of 77.7%
(95% CIs: 77.2–78.3) and a speciﬁcity of 77.8% (95% CIs: 77.3–78.2)
for the best high-dimensional model (ERT classiﬁer), compared
with an accuracy of 66.4% (95% CIs: 65.8–66.9), a sensitivity of
61.8% (95% CIs: 61.2–62.4) and a speciﬁcity of 66.8% (95% CIs:
66.2–67.5) for the best, conventional, low-dimensional model (ERT
classiﬁer). The superiority of the high-dimensional approach was
consistent across both types of machine learning classiﬁers (Fig.
1b, Table 1). Similar results were obtained with data balanced by
subsampling (see Supplementary Material). High-dimensional
models that incorporated volume and disconnectome dimensions
simultaneously achieved similar performance to those reported
above (results not shown). Null models constructed by randomly
permuting the order of values in each feature time series before
computing slopes, and thus trajectories, could not reliably detect
the intervention, conﬁrming that the observed performance was
not due to differences in scan timing (Table 2).
Fig. 1 Imaging response detection with low- and high-dimensional
models. a Receiver operating characteristic curves for imaging
response detection using the best high- and low-dimensional
models. Solid lines indicate the mean performance of each model,
and dashed lines the 95% conﬁdence intervals for the mean. b
Imaging response detection performance for each model and the
two types of classiﬁer obtained with two different machine learning
techniques. Bars indicate the mean performance of each model and
the lines the 95% conﬁdence intervals for the mean. Low-
dimensional models are drawn in blue, while the high-
dimensional models are drawn in red. Darker colour bars indicate
the support vector machine classiﬁers; the lighter colour bars
indicate the extremely randomised trees classiﬁers. All high-
dimensional models are seen to outperform the best low-
dimensional model, regardless of the classiﬁer used
Table 1. Imaging response detection performance of each model and
the two types of classiﬁer
Predictor set Support vector
machines
Extremely
randomised trees
Brain volume 0.554 [0.545–0.563] 0.595 [0.588–0.602]
Number of lesions 0.550 [0.540–0.561] 0.601 [0.594–0.609]
Total lesion volume 0.626 [0.618–0.634] 0.635 [0.629–0.641]
Best low
dimensional
0.647 [0.639–0.655] 0.686 [0.679–0.693]
Regional atrophy 0.857 [0.852–0.862] 0.819 [0.813–0.825]
Regional
disconnection
0.817 [0.810–0.824] 0.822 [0.815–0.828]
Best high
dimensional
0.869 [0.864–0.873] 0.890 [0.885–0.895]
The best high-dimensional model was constructed as one which provided
an average of the predictions made by the regional atrophy and the
regional disconnection models, weighted by their corresponding mean
AUCs. All ﬁgures are given as mean AUC [95% CI]
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Imaging features
The imaging features that were found to be most valuable for
detecting the imaging response to treatment (Fig. 2) and those
that comprised the best high-dimensional model based solely on
regional brain volume trajectories and the best high-dimensional
model based solely on regional brain volume disconnectome
trajectories (Fig. 3) were consistent with known patterns of lesion
and parenchymal change in multiple sclerosis. They were also
concordant in the direction of their effects (Fig. 4).
Confounders
The number of scans used for confounder regression and the
number of scans used speciﬁcally for the detection of imaging
response to treatment were 563 (124 patients) and 485 (103
patients), respectively. None of confounders could reliably be
predicted using the confounder adjusted imaging-derived
parameters, conﬁrming the absence of residual covariate effects
following confounder regression (Table 3).
The class distribution was 33.1% class 0 (pre-treatment) and
66.9% class 1 (post-treatment), while the robust performance
metrics of balanced F-scores and Matthews Correlation Coefﬁ-
cients also conﬁrmed the superiority of the high-dimensional
models (Tables 4 and 5).
Simulated, randomised, controlled trials
In simulated randomised controlled trials (RCTs) of the interven-
tion, the best high-dimensional model not only produced larger
odds ratios, but the odds ratios also scaled better with increasing
numbers of patients enrolled (Fig. 5a). Since the treatment effect
size here was ﬁxed, the improved odds ratios reﬂected better
statistical efﬁciency. A linear ﬁt to the data showed an increase in
the odds ratio, for every additional patient enrolled, of 0.3 for the
best high-dimensional model, compared with only 0.05 for the
best, conventional, low-dimensional model. In particular, mean
odds ratios with 59 patients enrolled were 5.83 (95% CIs:
5.17–6.49) and 10.6 (95% CIs: 9.38–11.7) for the conventional,
low- and the proposed, high-dimensional approaches, respec-
tively, diverging to 7.35 (95% CIs: 6.71–8.00) vs. 36.8 (95% CIs:
33.3–40.3) with 124 patients enrolled (Fig. 5a). As would be
expected, enrolling more subjects in a given RCT increased the
sensitivity with which an effect could be captured. However, Fig.
5a showed that this resulted in an early plateau in performance
using conventional, low-dimensional methods, while the steep
gradient in the odds ratio was strikingly persistent even at N= 124
with the proposed, high-dimensional methods. Therefore, while
one could achieve higher sensitivity in an RCT by increasing the
number of subjects enrolled, the beneﬁts were much more limited
with the conventional, low-dimensional approaches. The advan-
tages of the proposed, high-dimensional methods were also
apparent in the relation between the number of patients enrolled
in the RCT and the power of the study (Fig. 5b). For example, here
we saw that the statistical power achieved by the proposed, high-
and the conventional, low-dimensional models, respectively, were
Table 2. Imaging response detection performance of the null models
Predictor set Support vector
machines
Extremely
randomised trees
Brain volume 0.469 [0.463–0.475] 0.498 [0.490–0.506]
Number of lesions 0.457 [0.449–0.465] 0.464 [0.458–0.470]
Total lesion volume 0.473 [0.465–0.480] 0.535 [0.528–0.542]
Best low
dimensional
0.497 [0.490–0.503] 0.473 [0.467–0.480]
Regional atrophy 0.445 [0.437–0.453] 0.454 [0.447–0.461]
Regional
disconnection
0.465 [0.457–0.473] 0.467 [0.459–0.476]
Best high
dimensional
0.459 [0.450–0.469] 0.422 [0.414–0.430]
None of the null models could reliably detect the intervention. All ﬁgures
are given as mean AUC [95% CI]
Fig. 2 Regional brain volume and disconnectome trajectories most relevant to detecting the imaging response to treatment. The horizontal
axes show the maximum of the two mean areas under the receiver operating characteristic curve with 95% conﬁdence intervals obtained
using the SVM and ERT classiﬁers when each regional brain volume (a) and each regional disconnectome (b) predictor is used in isolation. The
following abbreviations have been used: OpIFG opercular part of the inferior frontal gyrus, TrIFG triangular part of the inferior frontal gyrus
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Fig. 3 Brain regions included in the best high-dimensional ERT model based solely on regional brain volume and disconnectome trajectories.
a The horizontal axis shows the mean area under the receiver operating characteristic (ROC) curve with 95% conﬁdence intervals as each
regional brain volume predictor is added to the model starting with the thalamus. b The horizontal axis shows the mean area under the ROC
curve with 95% conﬁdence intervals as each regional brain disconnectome predictor is added to the model starting with the supplementary
motor cortex. OpIFG opercular part of the inferior frontal gyrus, TrIFG triangular part of the inferior frontal gyrus
Fig. 4 Direction of association for four representative brain regions. This ﬁgure shows that, at the population level, and for two representative
regions, namely the thalamus (blue solid line) and the posterior cingulate gyrus (red solid line), we consistently observe atrophy (volume
decrease) in the pre-treatment period (t < 0) and stabilisation/recovery post-treatment (t > 0). For the degree of disconnection, and for two
other representative regions, namely the gyrus rectus (cyan dashed line) and the supplementary motor cortex (light brown dashed line), the
direction of association is the opposite (but clinically the same), namely an increase in the degree of disconnection in the pre-treatment
period and stabilisation/recovery post-treatment
B. Kanber et al.
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0.806 [95% CI= 0.698–0.872] compared with 0.508 [95% CI=
0.403–0.593] with N= 50, at a signiﬁcance level of α= 0.01 (Fig.
5b). Thus, in an RCT with 50 subjects enrolled, the risk of making a
type II error, in terms of hypothesis testing, was very signiﬁcant
with the conventional, low-dimensional approaches, while a
statistical power greater than 0.80 could be achieved at the same
N with the high-dimensional method. Although this difference
became smaller when the number of subjects enrolled in the RCT
was increased beyond 100, the individual-level prediction cap-
ability of the conventional, low-dimensional approaches lagged
increasingly more behind the proposed, high-dimensional meth-
ods (Fig. 5a).
DISCUSSION
This study has revealed a substantial difference between the
performance of conventional, low- and the proposed, high-
dimensional models of imaging response to treatment in multiple
sclerosis. We now turn to the interpretability, generalisability, and
potential real-world applications of our results.
A natural concern when dealing with high-dimensional models
is that they might ground their decision-making in imaging
changes that are not physiologically meaningful. But neither
changes in tissue loss nor degree of cortical disconnection can be
easily misinterpreted, especially when they are shown to be
reversals of familiar patterns of pathological change (Fig. 4).
Pseudoatrophy, a phenomenon associated with immunomodula-
tory drugs such as natalizumab, occurs in the ﬁrst 6 to 12 months
of treatment, not over the greater than 5-year period here
examined, and would be expected to produce the opposite
pattern of change.13–16
Care must be taken in interpreting high-dimensional models of
imaging response. Any imaging-based model will naturally be
sensitive to changes in proportion to their visibility on MR, not
their physiological impact. While the two go mostly hand-in-hand,
especially when the signal of interest is rate of tissue loss or
disconnection, it is important to establish an ultimate link to
clinical outcomes. But this is feasible only after a sensitive and
robust imaging response model is built, for a model trained
directly on clinical outcomes would inevitably conﬂate the two
sources of variability: that between treatment and imaging
changes and that between imaging changes and measured
clinical outcomes. Furthermore, a model of the imaging response
to treatment is independently valuable in multiple sclerosis,
indeed with any disseminated parenchymal pathology, owing to
the many areas of life impact conventional clinical measured do
not adequately capture.
The power of high-dimensional inference carries a risk: the
danger of ﬁnding a solution that is not generalisable beyond the
data on which the model has been trained. Contemporary
machine learning counters this risk by using out-of-sample testing
as the fundamental metric of performance, and algorithmic
characteristics that penalise purely local solutions. Key aspects of
our source data and modelling approach have further reduced
this risk. First, our patient sample was not just large but also
unselected, including everyone on our natalizumab register who
has been treated at our centres over an interval of 15 years.
Second, we deliberately kept our parameterisations of temporal
change and of anatomy relatively crude. The trajectories used to
estimate the former are dichotomised from purely linear models,
and the anatomical features used to describe the latter are
discretised into large brain regions. In the context of machine
learning inference, the ratio of input features to number of cases
was therefore kept conservative. All performance estimates were
obtained with out-of-sample testing, and we included metrics
robust to the class imbalance naturally observed within this
clinical pathway. Demonstrating robust performance in the face of
imbalanced data, without potentially unrealistic weighting or
Table 3. Veriﬁcation of the absence of residual confounder effects
following confounder regression
Confounder Before confounder
regression
After confounder
regression
Agea,b 0.645 [0.629–0.661] 0.483 [0.472–0.494]
Gender 0.723 [0.711–0.736] 0.488 [0.475–0.501]
Scanner manufacturerc 0.768 [0.756–0.780] 0.503 [0.487–0.519]
Field strengthd 0.803 [0.790–0.815] 0.503 [0.489–0.516]
Disease durationa,b 0.506 [0.493–0.519] 0.488 [0.477–0.499]
EDSSa,b 0.533 [0.511–0.555] 0.502 [0.483–0.521]
T1 slice thicknesse 0.522 [0.488–0.556] 0.442 [0.408–0.477]
T1 voxel resolutionb 0.789 [0.775–0.803] 0.497 [0.483–0.511]
FLAIR slice thicknesse 0.627 [0.591–0.662] 0.498 [0.474–0.523]
FLAIR voxel resolutionb 0.717 [0.699–0.736] 0.504 [0.491–0.517]
None of the confounders could reliably be predicted using the imaging
data by a support vector machine classiﬁer following confounder
regression. All ﬁgures are given as mean AUC [95% conﬁdence interval]
aAt the start of treatment with natalizumab
bPredicting whether the confounder value is less than the mean for the
sample population or otherwise
cThe most common manufacturer in the sample population vs. the rest
d1.5 T vs. 3.0 T
ePredicting whether the slice thickness is less than 6mm or otherwise
Table 4. Additional imaging response detection performance metrics
(balanced F-scores) for each model and the two types of classiﬁer
Predictor set Support vector
machines
Extremely
randomised trees
Brain volume 0.555 [0.541–0.569] 0.601 [0.593–0.609]
Number of lesions 0.595 [0.581–0.609] 0.666 [0.655–0.677]
Total lesion volume 0.602 [0.592–0.612] 0.619 [0.610–0.628]
Best low
dimensional
0.722 [0.713–0.731] 0.717 [0.708–0.725]
Regional atrophy 0.849 [0.843–0.855] 0.835 [0.829–0.842]
Regional
disconnection
0.821 [0.814–0.829] 0.816 [0.809–0.823]
Best high
dimensional
0.876 [0.870–0.882] 0.874 [0.868–0.880]
All ﬁgures are given as the mean, balanced F-score [95% CI]
Table 5. Additional imaging response detection performance metrics
(Matthews correlation coefﬁcients) for each model and the two types
of classiﬁer
Predictor set Support vector
machines
Extremely
randomised trees
Brain volume 0.132 [0.115–0.148] 0.179 [0.164–0.194]
Number of lesions 0.168 [0.152–0.184] 0.229 [0.214–0.243]
Total lesion volume 0.229 [0.213–0.245] 0.239 [0.223–0.255]
Best low-
dimensional
0.354 [0.339–0.369] 0.355 [0.341–0.369]
Regional atrophy 0.576 [0.563–0.590] 0.620 [0.607–0.633]
Regional
disconnection
0.544 [0.530–0.559] 0.559 [0.545–0.573]
Best high-
dimensional
0.666 [0.653–0.679] 0.675 [0.662–0.689]
All ﬁgures are given as the mean Matthews correlation coefﬁcient [95% CI]
B. Kanber et al.
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subsampling, strengthens the generalisability to real-world clinical
contexts.
How well the approach will extend to other treatments in
multiple sclerosis needs dedicated investigation, but since our
input features capture the major aspects of imaging any treatment
could conceivably modify—the patterns of lesional change and
regional atrophy—similar performance can reasonably be
expected. Indeed, where the treatment is less potent, or its
effects dispersed over a wider interval, the integrative power of
high-dimensional methods should amplify their beneﬁt.
Detecting an imaging response to treatment is a foundational
component of an array of possible applications with a focus either
on individual patients or on population mechanistic or therapeutic
aspects. Each presumes the prior availability of data of comparable
range and scale to that achieved here, from which an adequately
generalising model can be constructed, and against which new,
unlabelled data can be tested. The insensitivity of our approach to
scanner parameters—including the use of routine, clinical-grade
acquisitions—enables the generation of such datasets by pooling
heterogeneous data across disparate clinical units, without the need
for costly and logistically difﬁcult MR sequence optimisation. High-
dimensional modelling can thus be readily brought into practice.
A question which can be addressed in future studies is whether
the regional brain volume and disconnectome trajectories that were
detected as the “most important” are truly the most important
outcomes or are indirect measures of other changes or methodo-
logical issues such as the anisotropy of the clinical scans.
However, while high-quality, isotropic imaging is bound to
produce better “ﬁngerprints” of response and may alter the
contribution of brain areas thereby more reliably quantiﬁed,
imaging only practicable in specialist academic centres is here
shown to be unnecessary (even if always desirable) and would
likely maintain or amplify the advantage of our approach.
Where the pattern of detected change is convincingly an arrest
or reversal of the pathological, it may be used as an independent
measure of response to treatment in a speciﬁc patient, collaterally
with clinical measures. Such a use is logically identical with
counting the number of new lesions or other established
radiologist-derived metrics, differing only in its sensitivity. As with
any other radiological metric, corroboration by subsequent clinical
evolution would be an important part of its development. Second,
the pattern of detected change may be used to interpret
individual clinical changes with greater precision. For example,
where the pattern of cortical disconnection or atrophy is shown to
impinge heavily on areas of the brain concerned with cognition,
motor clinical measures are likely to be much less sensitive than
cognitive ones, and ought to be commensurately weighted.
Determining the speciﬁc contribution of any one factor within a
given population of patients naturally depends on our ability to
model the many confounding factors that contribute to the
outcome of interest. Where the variability introduced by
confounders is treated simply as noise the sensitivity for detecting
the effect of the factor we seek is commensurately reduced. In a
randomised controlled trial of an intervention, a better model of
the imaging outcome thus enhances our ability to detect a true
imaging response to treatment, and should be used where this is
an independent outcome of interest. Such a model would also
enhance our ability to identify incidental factors that interact with
the treatment, enabling us better to identify biological features
that modulate treatment responsiveness. Where the outcome of
interest is purely clinical, capturing its high-dimensional imaging
Fig. 5 Simulated randomised controlled trials (RCT) of the
intervention incorporating varying numbers of patients. Each RCT
is simulated by randomly choosing a subset of N patients and
evaluating the association between classiﬁer output and imaging
response with a Fisher’s exact test. The procedure is repeated 500
times, yielding a mean odds ratio (panel a, solid lines), and a mean
achieved statistical power given a signiﬁcance level of α= 0.01
(panel b, solid lines), along with 95% conﬁdence interval (both
panels, dotted lines) for each N. RCTs in red use the best performing
high-dimensional model to detect the response, while RCTs in blue
use the best performing low-dimensional model. a The odds ratio. It
is seen that, if one performs an RCT with 124 patients enrolled, the
odds ratio is 36.8 if one uses the high-dimensional method vs. only
7.35 if one uses a traditional low-dimensional approach. RCTs using
the high-dimensional model not only produce larger odds ratios,
but they also scale better with increasing patient numbers. b The
achieved statistical power. We see that the statistical power
achieved by the high- and low-dimensional models, respectively,
are 0.806 [95% CI= 0.698–0.872] and 0.508 [95% CI= 0.403–0.593]
with N= 50, at a signiﬁcance level of α= 0.01. Thus in an RCT with
50 subjects enrolled, the risk of making a type II error is very
signiﬁcant with the traditional low-dimensional approaches, while a
statistical power greater than 0.80 can be achieved at the same N
with the high-dimensional method
B. Kanber et al.
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correlates allows us to weight the predicted clinical eloquence of
the treatment effect, enhancing its detection. The imaging
response is here used to deconfound the clinical from the
interaction between disease patterns and the underlying func-
tional anatomy. Naturally, these applications will require more
than the imaging response models on which they are all founded,
but our objective here is to outline the horizon of possibilities our
general approach discloses.
The clinical implication of applying high-dimensional modelling to
predict the imaging response to a treatment to patients with
multiple sclerosis is that individual patients may be counselled about
their probability of responding to a speciﬁc therapy prior to
treatment initiation, or soon after, thereby increasing the possibility
of initiating the most effective treatment for their individual disease
proﬁle. Pharmacological companies may use the individual predic-
tion of treatment response provided by this technology to select
patients who are more likely to respond to a speciﬁc therapy, with
consequent reduction in the sample size and cost of the trial.
Therefore, the future impact of this technology is to improve patient
management and treatment, and facilitate the testing of drug
efﬁcacy and monitoring of treatment response.
In conclusion, this study demonstrates the value of modelling
routine imaging data with high-dimensional techniques that closely
reﬂect the complexity of the brain, not only as a tool for illuminating
diseases mechanisms, but as a practical, real-world means of
determining the power of therapeutic interventions to change them,
both for individual patient care and interventional studies.
METHODS
Patients and MRI
We identiﬁed relapsing–remitting multiple sclerosis patients treated with
natalizumab at the National Hospital for Neurology and Neurosurgery,
University College London Hospitals NHS Foundation Trust, London, UK,
according to local, standard-of-care protocols, for whom at least one full-
brain scan pre- or post-initiation of natalizumab was available. This yielded
imaging data from 124 patients (563 scans from 2001 to 2016), acquired
using routine, clinical MRI protocols with six different 1.5 T or 3 T scanners
(Siemens, Philips, and GE), all of which were irrevocably anonymised.
Clinical characteristics of the patients corresponded to the standard clinical
indications for initiating natalizumab in the UK, where natalizumab is
licensed as a second-line treatment, and were typical of such cohorts
(Table 6, Supplementary Table 1).
Our analysis used T1-weighted and ﬂuid-attenuated inversion recovery
(FLAIR) scans, having an average voxel resolution of 1 × 1 × 6mm3, which is
typical of routine, standard-of-care, brain MR imaging in the UK.
Acquisition and other instrumental parameters varied both across and
within patients.
The study had ethical and institutional approval at University College
London Hospitals NHS Foundation Trust for consentless analysis of fully-
anonymised, routinely collected data and was performed in accordance
with the relevant guidelines and regulations.
Image processing and feature extraction
To construct models of imaging response, we extracted a rich, multivariate
set of parameters from each image—an imaging “ﬁngerprint”—and
monitored their evolution over the available time series. To minimise bias
and maximise practicability, all processing was fully automated.17 We
implemented well-established solutions to each of the three necessary
steps: anatomical registration and regional brain parcellation, lesion
segmentation and brain disconnection estimation (“disconnectome”)
(Fig. 6). In brief, the Geodesic Information Flows (GIF) method18 was
applied to each T1-weighted image to generate a set of 144 regions-of-
interest, both natively and in standard Montreal Neurological Institute 152
(MNI152) stereotactic space. The GIF method has previously been
successfully used for the parcellation of anisotropic brain MR images.7,19,20
In parallel, focal white matter lesions were segmented from the FLAIR
images in conjunction with the T1 data using a dual-modality approach,
combining patch match21 and expectation maximisation algorithms,22 also
both natively and in MNI152 space. The resultant lesion masks were
checked and validated by a neurologist (RC) and a neuroradiologist (FB): all
were found to be satisfactory. Finally, we computed whole-brain, voxel-
wise, probabilistic maps of disconnection in MNI152 space23–25 using the
Brain Connectivity and Behaviour toolkit.26 This toolkit estimates the
probability of disconnection of each brain region by combining the
localisation of the white matter damage with a probabilistic tractographic
atlas. Each white matter lesion is thus projected to the brain regions
connected by the tracts it disrupts (see Fig. 6).
The outputs from these steps were total lesion volume, number of
lesions, total brain volume, and a high-dimensional imaging “ﬁngerprint”
of 288 variables, incorporating regional brain volumes within the GIF
parcellation, and their estimated degrees of disconnection (Table 7).
Confounder removal
To facilitate the extraction of the signal of interest—the speciﬁc effect of
the intervention—it is desirable to minimise variability arising from other
factors with a bearing on the appearance of the brain. The covariates of
age, gender, scanner manufacturer, magnetic ﬁeld strength, disease
duration, Expanded Disability Status Scale (EDSS) score, and voxel size
(T1 and FLAIR) were therefore regressed out of all the imaging-derived
parameters using BayesReg.27 Such cofounder removal is kin with the
covariance adjustment widely used in trials and observational studies.28
Total lesion volume, total brain volume and regional brain volumes were
normalised by the total intracranial volume. To conﬁrm that the
confounders were successfully removed,29,30 we separately ﬁtted multi-
variate models attempting to predict them and conﬁrmed that they could
not. All subsequent analyses used regional and global parameters
deconfounded in this way.
Longitudinal feature extraction
Our objective is to detect a difference—before and after the start of
treatment—of the rate of change of the imaging-derived parameters. The
rate of change is simply quantiﬁed by the slope of a line ﬁtted to two or
more points dispersed over time. We therefore performed—independently
for each variable—linear regression on the sets of available scans before
and after the start of treatment, taking the slope as a measure of the rate
of change of the relevant parameter over time (Fig. 7). For example, the
normalised volume of the thalamus, indexed on each of the pre-treatment
scans, was linearly regressed against time to yield a pre-treatment slope,
and the same was done on the post-treatment scans to yield a post-
treatment slope. The process was replicated for each area and each
patient, and for both volumes and disconnections, yielding two sets of
slopes for each patient—before and after treatment—for each of the 288
variables and their derived low-dimensional aggregates. For some patients
only a pre-treatment (N= 16) or post-treatment (N= 60) slope was
available for reasons of data non-availability.
Table 6. Patient demographics and clinical characteristics
Number of patients (N) 124
Gender 44 M, 80 F
Age, yearsa,b 38 (20–70)
Weight, kgb 70.3 (45–111)
Disease duration, yearsa,
c
6.3 (2.2)
EDSSa,c 4.8 (1.7)
Length of follow-up,
yearsc
4.2 (2.6)
Previous therapyd 63 (50.8%)—beta interferons
31 (25.0%)—beta interferons and copaxone
14 (11.3%)—copaxone
16 (12.9%)—other medications/medicine
combinations
aAt the start of treatment
bMean (range)
cMean (standard deviation)
dNumber (%) of patients
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The accuracy of slope estimates will inevitably vary with the number and
timing of individual scans. To minimise any resultant confounding effects,
we converted each slope to a trajectory by taking its sign, yielding +1 for a
positive slope, and −1 for a negative slope (Fig. 7). Where a slope is exactly
0, e.g. for ordinal or bounded variables, a third class denoting no change
(slope= 0) was introduced. Note that the cost of minimising potential bias
here is loss of some information on the relatively reliability of each slope
estimate, reducing our ability to reject noise arising from variability over
short intervals. A potential reduction in sensitivity is, however, preferable
to retaining information that might be a source of bias. Equally, though
greater sensitivity could be achieved by explicitly modelling global, disease
non-speciﬁc effects of an intervention such as pseudoatrophy, the risk of
introducing bias motivates us to desist.
Since only relatively weak, population-level lateralisation of the impact
of multiple sclerosis on the brain has been observed, and there are no
grounds for expecting lateralised treatment effects, we collapsed
trajectories across homologous regions of each hemisphere, taking the
sum of the trajectories for each pair. This increases the compactness of our
models without likely substantial loss of information.
Models of imaging response
To quantify the effect of dimensionality on our ability to detect an imaging
response to treatment, we evaluated the performance of conventional,
low- and the proposed, high-dimensional models in detecting whether a
set of trajectories belonged to the pre- or post-treatment period. The
outcome was, therefore, our ability to differentiate between measurements
made in the pre- vs. post-treatment period. We used two different
classiﬁers: support vector machines (SVM)31 and extremely randomised
trees (ERT)32 implemented in scikit-learn.33 They were chosen as
representative of two different, widely used architectures that exhibit
different degrees of ﬂexibility, the latter greater than the former, allowing
us to explore the effects of maximal model capacity independently of the
input dimensionality.
Cross-validation was performed using bootstrapping (500 iterations),
fully holding-out each test set, and randomly allocating 80% of the cases
for training and 20% for testing at each iteration (Supplementary code
snippet 1). The randomisation and bootstrapping were carried out at the
subject level and were constrained to prevent the selection of the same
patient’s data for both training and testing at the same time, in the case of
patients who had both pre- and post-natalizumab trajectories available (N
= 27). The parameters of the two classiﬁers were tuned manually (with the
same bootstrapped, out-of-fold, cross-validated setup described above and
shown in Supplementary code snippet 1), the ﬁnal settings are given in
Table 8.
Feature and model selection
We used the greedy, forward-stepwise feature selection algorithm shown
in Supplementary code snippet 2 which utilises the mean bootstrapped,
Table 7. Processing steps and the parameters derived
Processing step Input Output
Regional parcellation T1 144 regional brain volumes, total brain volume
Lesion segmentation T1 & FLAIR Total lesion volume, number of lesions
Disconnectome estimation Lesion segmentation 144 regional brain disconnection estimates
Fig. 6 Extracting a high-dimensional imaging “ﬁngerprint”. The T1-weighted MRI volume is used to obtain the regional parcellation of the
brain, and alongside the FLAIR to detect white matter lesions. The brain “disconnectome”, which is subsequently obtained using the detected
lesion mask, is a probabilistic map of regional disconnection. The degree of disconnection is colour coded, so that grey matter regions that
appear more yellow in the disconnectome map are predicted to have higher degrees of disconnection, due to the presence of the multiple
sclerosis lesions in the white matter tracts that are connected to them, than regions which appear in red. The output from all these steps,
following slope and trajectory calculation, is a high-dimensional imaging “ﬁngerprint” comprising the trajectories of the normalised regional
brain volumes and the degrees of disconnection for each of the regions in the brain parcellation
B. Kanber et al.
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out-of-fold, cross-validation AUC as the performance measure. This
approach is preferable over the use of feature importances that can be
obtained from classiﬁers such as randomised trees. Unlike the latter which
measure feature importances based on the in-fold data they see during
training, the importance of each feature in our method is measured using
bootstrapped, out-of-fold, cross-validation, thus giving unbiased perfor-
mance estimates.
The selection of low- and high-dimensional features, and in the case of
the latter, the selection of regional volume, and regional disconnectome
features were carried out separately. Our ﬁnal predictors were then the
trajectories of the number of lesions, total lesion volume, and total brain
volume (for the conventional, low-dimensional case), and a high-
dimensional “imaging ﬁngerprint”, which incorporated the trajectories of
23 lesion- and 20 tissue-derived features extracted from MR images
acquired at pre- or post-treatment patient visits.
Once the selection of regional volume and the disconnectome features
was completed, the best high-dimensional model was then constructed as
one which provided a weighted average of the predictions made by the
best high-dimensional model based solely on regional brain volume
trajectories, and the best high-dimensional model based solely on regional
brain disconnectome trajectories. This approach was chosen over one
which incorporates both dimensions simultaneously as it allows us to test
the performance of models that incorporate only volumetric and
disconnectome metrics, while providing a clearer understanding of which
volumetric and disconnectome measures contribute more to imaging
response detection. Feature selection was carried out once and the same
features were subsequently used throughout.
Performance evaluation
Receiver operating characteristic (ROC) curves were used to quantify the
detection performance of each model, qualiﬁed statistically by the area
under the ROC curve (AUC), accuracy, sensitivity and speciﬁcity. Two-sided,
two-sample Kolmogorov–Smirnov tests were used for statistical validation
and signiﬁcance values less than 0.05 were considered statistically
signiﬁcant. Performance values were aggregated with respect to boot-
straps in terms of the mean and the standard error.
We also investigated the performance of conventional, low-dimensional
and the proposed, high-dimensional models to detect the imaging
response to treatment in simulated, RCTs of the intervention enrolling
varying numbers of patients (ranging from 19 to 124 in number). Each RCT
was simulated by randomly choosing a subset of N patients and evaluating
the association between classiﬁer output and imaging response with
Fisher’s exact test. The procedure was repeated 500 times, yielding for
each N a mean odds ratio and an achieved power given a signiﬁcance
threshold of α= 0.01, both with 95% conﬁdence intervals. Statistical power
calculations were performed with the G*Power34 software.
Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Due to ethical concerns, supporting data cannot be made openly available. Further
information about the data that support the ﬁndings of this study is available from
the corresponding author upon reasonable request.
Fig. 7 Illustration of the slope of an imaging metric between two
pre-treatment scans, and the different potential slopes between two
subsequent post-treatment scans, showing how these are scored. a
In the pre-treatment period the imaging metric, e.g. the normalised
volume of the thalamus is decreasing in both the left and the right
hemispheres, thus each has a trajectory of −1, leading to a net
trajectory of −2. In the post-treatment period, the normalised
volume of the left thalamus is increasing, while we illustrate two
differential scenarios: one in which the normalised volume of the
right thalamus is continuing to decrease, and one which the
normalised volume is increasing, leading to net trajectories for the
normalised volume of the thalamus of 0, and +2, respectively. b In
the pre-treatment period the imaging metric, e.g. the degree of
disconnection of the thalamus is increasing in both the left and the
right hemispheres, thus each has a trajectory of 1, leading to a net
trajectory of +2. In the post-treatment period, the degree of
disconnection of the right thalamus is getting smaller, while we
illustrate two differential scenarios: one in which the degree of
disconnection of the left thalamus is continuing to increase, and
one which the degree of disconnection is getting smaller, leading to
net trajectories for the degree of disconnection of the thalamus of 0,
and −2, respectively
Table 8. Final parameters of the two types of machine learning
classiﬁers used
Classiﬁer Final parameters and settings
SVM Gaussian radial basis function kernel, penalty term C= 10
(with balanced class weighting), kernel coefﬁcient
γ= number of features−1
ERT Gini impurity as the tree-splitting metric, number of
trees= 100, number of features to consider when looking
for the best split Mf= number of features1/2, balanced class
weighting
SVM support vector machines, ERT extremely randomised trees
B. Kanber et al.
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CODE AVAILABILITY
The software used in this study were as follows: Python 2.7 (https://www.python.org/
), scikit-learn 0.19.2 (https://scikit-learn.org), Numpy 1.15.4 (http://www.numpy.org/),
Scipy 1.1.0 (https://www.scipy.org/), Brain Connectivity and Behaviour toolkit 2018
(http://toolkit.bcblab.com/), GIF v3 (http://niftyweb.cs.ucl.ac.uk/program.php?p=GIF),
BayesReg 1.8.0.1 (https://www.mathworks.com/matlabcentral/ﬁleexchange/60823-
bayesian-penalized-regression-with-continuous-shrinkage-prio), G*Power 3 (http://
www.gpower.hhu.de/), MATLAB 2018 (https://www.mathworks.com), NiftyReg
(https://github.com/KCL-BMEIS/niftyreg/wiki). All software are open-source/publicly
available, except for GIF v3, and MATLAB, which are commercial packages.
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